Canonical product evidence map
AOD-9604 Evidence Map
A source-linked map of clinical-development, preclinical, analytical and FDA compounding-review records for AOD-9604.
- 3
- unique source records
- 2
- research types
- 2004–2024
- source-year range
Evidence distribution
See the source mix before reading the conclusions.
A large record count does not imply mature human evidence. The model and source type determine which question a record can answer.
Research type
Regulatory or database record2
Narrative review1
Study model
Regulatory / database2
Mixed / review1
Source-linked records
3 records connected to AOD-9604
Records are deduplicated by canonical source URL and keep their model, type and evidence-tier labels visible.
001
Regulatory / authoritativeRegulatory / database2024
FDA Evaluation of AOD-9604-Related Bulk Drug Substances
U.S. FDA. December 4, 2024 Pharmacy Compounding Advisory Committee briefing document.
Regulatory or database recordOpen source ↗
002
Context — Narrative reviewMixed / review2004
AOD-9604 development review
Wilding J. Current Opinion in Investigational Drugs. 2004. PMID 15134286.
Narrative reviewReviewOpen source ↗
003
Regulatory / authoritativeRegulatory / databaseUndated
FDA December 2024 PCAC meeting record
Regulatory meeting context.
Regulatory or database recordOpen source ↗
Evidence boundary
A source set is not a clinical recommendation.
- Human, animal, in-vitro, analytical, registry and regulatory records remain separate evidence categories.
- A published intervention or approved finished medicine does not verify the identity or quality of a catalog research lot.
- Record inclusion does not mean every finding has been independently replicated or applies outside its stated population and model.
Continue researching